Financing round of €12 million closed, including grant funding, led by SPRIND (the German Federal Agency for Breakthrough Innovation) and Huma, with participation from private investors

完成1200万欧元融资轮次，包括资助资金，由德国联邦突破式创新机构（SPRIND）和Huma领投，私人投资者参与

Proceeds fund a Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), plus upcoming Phase I read-outs in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC)

所得资金将用于资助CLLTAXS01在慢性淋巴细胞白血病（CLL）中的II期临床试验，以及即将公布的在急性髓系白血病（AML）和纤维板层型肝癌（FLC）中的I期临床试验结果。

TÜBINGEN, Germany

德国图宾根

,

，

Sept. 23, 2026

2026年9月23日

/PRNewswire/ -- ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors, today announced the close of the Series A financing round of up to €12 million, including grant funding. The round was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with participation from private investors..

/美通社/ -- 专注于开发用于血液恶性肿瘤和实体瘤的肽基癌症免疫疗法的临床阶段生物技术公司ViferaXS，今日宣布完成高达1,200万欧元的A轮融资（包括赠款资金）。本轮融资由德国联邦突破性创新机构SPRIND和Huma领投，并有私人投资者参与。

The proceeds will fund ViferaXS' lead programme, a Phase II clinical trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), and support ViferaXS' broader pipeline. In parallel, the financing supports ongoing Phase I programmes in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC). Beyond these programs, the round enables ViferaXS to grow its team and advance preclinical work in further indications..

所得资金将用于资助ViferaXS的核心项目，即CLLTAXS01在慢性淋巴细胞白血病（CLL）中的II期临床试验，并支持ViferaXS更广泛的研发管线。同时，该融资还支持正在进行的急性髓系白血病（AML）和纤维板层型肝癌（FLC）的I期项目。除这些项目外，本轮融资还使ViferaXS能够扩大团队规模，并推进针对其他适应症的临床前研究。

'We are encouraged by the early clinical data of CLLTAXS01, and this financing lets us move that signal into a randomized Phase II study in CLL. We also expect to share Phase I data from our AML and FLC programs soon, so the field can see how a peptide-based cancer immunotherapy approach can potentially transform cancer care for patients,' said .

“CLLTAXS01的早期临床数据令人鼓舞，此次融资使我们能够将这一积极信号推进至慢性淋巴细胞白血病（CLL）的随机II期研究。我们还预计不久将分享来自急性髓系白血病（AML）和滤泡性淋巴瘤（FLC）项目的I期数据，让业界看到基于肽的癌症免疫疗法如何有望变革患者的癌症治疗格局。”

Sezai Taskin

塞扎伊·塔什金

, Chief Executive Officer of ViferaXS.

ViferaXS 首席执行官。

'SPRIND believes in challenging the status quo by backing change makers. ViferaXS' peptide-based cancer immunotherapy approach, and its move into Phase II in CLL, is the kind of clinically grounded, high-ambition work we seek to accelerate. Our goal is to empower novel, breakthrough approaches, which we believe will have a long lasting and breakthrough positive effect on society' said .

“SPRIND 坚信通过支持变革者来挑战现状。ViferaXS 基于肽的癌症免疫疗法方法，以及其在慢性淋巴细胞白血病（CLL）治疗中进入二期临床试验的举措，正是我们致力于加速推进的那种具有坚实临床基础且雄心勃勃的工作。我们的目标是赋能新颖的突破性方法，我们相信这些方法将对社会产生持久且突破性的积极影响。”

Patrick Rose

帕特里克·罗斯

, PhD, Innovation Manager at SPRIND.

博士，SPRIND 创新经理。

Dan Vahdat

丹·瓦赫达特

, Founder and CEO of Huma, said: 'We are building the operating system for clinical trials, bringing data, intelligence and execution into one platform. We are proud to back ViferaXS through both our investment and our technology, helping accelerate its mission to bring new cancer therapies to patients.'.

Huma 创始人兼首席执行官表示：“我们正在构建临床试验的操作系统，将数据、智能和执行整合到一个平台中。我们很自豪能够通过投资和我们的技术支持 ViferaXS，帮助加速其为患者带来新癌症疗法的使命。”

About ViferaXS

关于 ViferaXS

ViferaXS GmbH is a clinical-stage biotechnology company and a spin-out of the Eberhard Karls University Tübingen based in Tübingen, Germany, developing cancer immunotherapies for hematologic malignancies and solid tumors. The company's core platform is a proprietary T Cell Activator technology designed to activate cytotoxic T cells against naturally presented tumor antigens.

ViferaXS GmbH 是一家处于临床阶段的生物技术公司，脱胎于德国蒂宾根的埃伯哈德·卡尔·蒂宾根大学，总部位于德国蒂宾根，致力于开发针对血液系统恶性肿瘤和实体瘤的癌症免疫疗法。该公司的核心平台是一项专有的 T 细胞激活剂技术，旨在激活细胞毒性 T 细胞，以对抗自然呈递的肿瘤抗原。

The clinical pipeline spans three oncology indications: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and fibrolamellar carcinoma (FLC)..

临床研发管线涵盖三个肿瘤适应症：急性髓系白血病（AML）、慢性淋巴细胞白血病（CLL）和纤维板层型肝癌（FLC）。

About SPRIND

关于 SPRIND

SPRIND, the German Federal Agency for Breakthrough Innovation, funds and supports breakthrough innovations with significant societal and economic impact. Founded in 2019 and owned by the Federal Republic of Germany, SPRIND exists to advance high-ambition projects for which private-sector funding alone is often insufficient, and to help keep the value of those innovations in Germany and Europe..

德国联邦突破性创新机构（SPRIND）为具有重大社会和经济影响的突破性创新提供资金和支持。SPRIND成立于2019年，隶属于德意志联邦共和国，其宗旨是推进那些仅靠私营部门资金往往不足以支持的高雄心项目，并帮助将这些创新的价值保留在德国和欧洲。

About Huma

关于 Huma

Huma is building the operating system for AI in regulated industries. Founded in healthcare, Huma enables governments, healthcare systems, life sciences companies and other regulated organisations to build, deploy and scale AI-powered applications and workflows.

Huma 正在为受监管行业构建人工智能操作系统。Huma 起源于医疗健康领域，助力政府、医疗卫生体系、生命科学公司及其他受监管机构构建、部署和扩展基于人工智能的应用程序与工作流。

Huma brings together data, AI, applications and regulatory infrastructure in a single platform, powering production-grade AI across mission-critical environments worldwide.

Huma 将数据、人工智能、应用程序和监管基础设施整合于单一平台，为全球关键任务环境中的生产级人工智能提供动力。

SOURCE ViferaXS GmbH

来源：ViferaXS 有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示